海博刀分次立体定向放疗后手术腔与完整脑转移瘤的不良放射效应风险分析
中位总剂量30 Gy,中位随访12个月。结果显示完整转移瘤的ARE风险高于手术腔,完整转移瘤中BMC30是症状性ARE的预测因素,阈值10.5 cm3可能指导治疗计划。
要点
- 完整转移瘤较手术腔有更高的症状性ARE风险(OR 3.65)。
- 手术腔HSRS中,既往全脑放疗和立体定向放疗是症状性ARE的预测因素。
- 完整转移瘤中,BMC30>10.5 cm3与症状性ARE风险增加相关(OR 7.21)。
核心结论
- HSRS后完整转移瘤的ARE风险高于手术腔。
- 完整转移瘤中BMC30可预测症状性坏死,阈值10.5 cm3可能指导治疗计划。
研究设计与样本
- 所有患者接受5次每日分次HSRS,计划靶体积外放2 mm。
- 评估临床和剂量学变量以识别ARE预测因素。
主要发现
- 中位总处方剂量30 Gy(范围20-35 Gy),中位随访12个月。
- 手术腔和完整转移瘤的中位计划靶体积分别为24.9 cm3和7.7 cm3。
- ARE和症状性ARE发生率分别为21.2%和10.8%,中位发生时间8个月。
- 多变量分析显示完整转移瘤对比手术腔是症状性ARE的显著预测因素(OR 3.65;95%CI 1.33-10)。
关键数值与推荐
- 手术腔HSRS中,既往全脑放疗(OR 7.73;95%CI 1.67-35.69)和既往立体定向放疗(OR 8.66;95%CI 1.14-65.7)是症状性ARE的显著预测因素。
- 完整转移瘤中,BMC30是症状性ARE的显著预测因素(OR 1.21;95%CI 1.02-1.43)。
- BMC30体积阈值10.5 cm3显著(OR 7.21;95%CI 1.31-39.45)。
临床怎么用
- 对完整脑转移瘤行HSRS时,应关注BMC30,阈值10.5 cm3可辅助治疗计划。
- 对手术腔行HSRS时,需考虑既往全脑放疗或立体定向放疗史以评估症状性ARE风险。
局限性
- 回顾性研究设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Limited data exist quantifying the risk of adverse radiation effect (ARE) specific to hypofractionated stereotactic radiosurgery (HSRS). We present our analyses of the risk of ARE after 5 daily fractions of HSRS to surgical cavities and intact metastases. METHODS AND MATERIALS: One hundred and eighty-seven consecutively treated patients with 118 surgical cavities and 132 intact metastases were retrospectively reviewed. All patients were treated with 5 daily fractions with a 2 mm planning target volume applied. Clinical and dosimetric variables were assessed to identify predictors of ARE. RESULTS: The median total prescribed dose was 30 Gy (range, 20-35 Gy) and median follow-up was 12 months. One hundred forty-four patients (77%) received treatment to a single target. Median planning target volumes for resection cavity and intact metastases were 24.9 cm3 and 7.7 cm3, respectively. ARE and symptomatic ARE were observed 21.2% and 10.8% of targets, respectively, and the median time to ARE was 8 months. Time to ARE was <6 months for 38%, 6 to 12 months for 43%, and >12 months for 19% of targets. Multivariable analysis identified intact metastases versus cavities (odds ratio [OR], 3.65; 95% confidence interval [CI], 1.33-10) as a significant predictor of symptomatic ARE. Specific to cavity HSRS, prior whole brain radiation therapy (OR 7.73; 95% CI, 1.67-35.69) and prior stereotactic radiosurgery (OR 8.66; 95% CI, 1.14-65.7) were significant predictors of symptomatic ARE. For intact metastases, the total brain minus gross tumor volume (GTV) receiving 30 Gy (BMC30) was a significant predictor of symptomatic ARE (OR, 1.21; 95% CI, 1.02-1.43), and a volume-based BMC30 threshold of 10.5 cm3 was significant with an OR of 7.21 (95% CI, 1.31-39.45). CONCLUSIONS: The risk of ARE was greater for intact metastases compared with cavities after HSRS. For intact lesions, the BMC30 was predictive for symptomatic necrosis, and a threshold of 10.5 cm3 may guide treatment planning.
引用
- Faruqi S, Ruschin M, Soliman H, et al. Adverse Radiation Effect After Hypofractionated Stereotactic Radiosurgery in 5 Daily Fractions for Surgical Cavities and Intact Brain Metastases. Int J Radiat Oncol Biol Phys. 2020. PMID: 31928848. doi:10.1016/j.ijrobp.2019.12.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。